Featured Research

from universities, journals, and other organizations

'License To Kill' Enables Powerful Immune Attack Cells In Mice

Date:
August 4, 2005
Source:
Washington University School of Medicine
Summary:
Scientists have discovered that a group of important immune system cells has a surprising resemblance to cinematic British superspy James Bond: the cells receive a "license" that allows them to unleash their most potent attacks on enemies.

Scientists have discovered that a group of important immune systemcells has a surprising resemblance to cinematic British superspy JamesBond: the cells receive a "license" that allows them to unleash theirmost potent attacks on enemies.

This licensing process apparently helps reduce the chances that thecells will erroneously direct their firepower at the body's owntissues, according to researchers at Washington University School ofMedicine in St. Louis. The process is very different from otherpreviously identified ways that help immune cells distinguish invadersfrom self, and could have important implications for doctors strugglingto understand such issues as persistent viral infections and patients'responses to bone marrow transplants. The findings will appear in theAugust 4 issue of Nature.

The immune cells in question already evoked cinematic connectionssimply by virtue of one of their names: scientists commonly refer tothem as natural killer cells. The cells rapidly attack invaders and arecontinually generated in the bone marrow, leading to replacement of theentire population approximately once a week.

Scientists led by Wayne M. Yokoyama, M.D., the Sam J. Levin and AudreyLoew Levin Professor of Research in Arthritis, and professor ofmedicine and of pathology and immunology, discovered throughexperiments in mice that the arsenals of natural killer cells onlybecome fully armed after a receptor on their surfaces interacts with amolecule on the surfaces of other cells.

The molecular details of the process were so unusual that Yokoyama andhis colleagues found themselves struggling to develop terms to describeit to other immunologists.

"So many other terms that might have been appropriate--education,tolerance, instruction, selection--already have specialized meanings inimmunology that really aren't appropriate for this unique process we'vediscovered," says Yokoyama, who is a Howard Hughes Medical InstituteInvestigator and chief of the Division of Rheumatology at Barnes-JewishHospital. "Many of these terms refer to processes with a similaroutcome--improved ability to distinguish between self and non-self--butthis is a very different way of reaching that goal. So we came up withthe term licensing."

Their results include another ironic connection to the world of cinemaspies: the molecular details of the process feature a player who iscomparable to a double agent. Scientists have known for some time thatnatural killer cells have inhibitory receptors on their surfaces.

The natural killer cells' ability to attack is inhibited whenthese receptors encounter a molecule known as major hiscompatibilitycomplex (MHC) class I on the surface of other cells. MHC serves as akind of molecular I.D. badge, helping the natural killer cells todistinguish the self from an invader.

But Yokoyama's group found that the inhibitory receptors switch rolesduring licensing. Although the structure of the receptors is exactlythe same in immature natural killer cells, they act not as inhibitorsbut as enablers. In their studies, natural killer cells in mice becamemuch more capable of mounting attacks against invaders after they firstencountered the mouse version of MHC.

"The structure of these receptors on human natural killer cellsis different from the mouse version, but they have a similar function,"says lead author Sungjin Kim, Ph.D., research instructor inrheumatology. "We will be looking for a way to see if the human versionalso participates in some kind of licensing process."

The group's research was made possible by a unique mouse line createdby Ted H. Hansen, Ph.D., professor of pathology and immunology and ofgenetics. Mice normally have many different versions of the MHCmolecule, but Hansen created a line that makes only one. This wasessential to the ability of Yokoyama's group to test its hypothesis.

The new findings from Yokoyama's laboratory could explain some puzzlingoutcomes in the clinic, including why some patients with hepatitis Cinfections can be cured while others have a chronic infection for therest of their lives.

"This could be an important advance both conceptually and in terms ofclinical practice," Yokoyama says. "It could also help us match bonemarrow transplants in a way that increases the immune system's abilityto fight off a relapse of the leukemia."

###

Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song Y-J, Yang L,French AR, Sunwoo1 JB, Lemieux S, Hansen TH, and Yokoyama WM. Licensingof natural killer cells by host MHC class I. Nature, August 4, 2005.

Funding from the Howard Hughes Medical Institute, the NationalInstitute of Allergy and Infectious Diseases, the Rheumatic DiseaseCore Center at Washington University, and the Barnes-Jewish HospitalFoundation supported this research.


Story Source:

The above story is based on materials provided by Washington University School of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Washington University School of Medicine. "'License To Kill' Enables Powerful Immune Attack Cells In Mice." ScienceDaily. ScienceDaily, 4 August 2005. <www.sciencedaily.com/releases/2005/08/050804053141.htm>.
Washington University School of Medicine. (2005, August 4). 'License To Kill' Enables Powerful Immune Attack Cells In Mice. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2005/08/050804053141.htm
Washington University School of Medicine. "'License To Kill' Enables Powerful Immune Attack Cells In Mice." ScienceDaily. www.sciencedaily.com/releases/2005/08/050804053141.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins